
FDA greenlights Celltrion HIV drug manufacturing facility in South Korea
pharmafile | March 16, 2020 | News story | Manufacturing and Production, Sales and Marketing | FDA, celltrion, coronavirus, pharma
South Korean biopharma firm Celltrion has revealed that one of its key manufacturing facilities has been given the all-clear by the FDA following an on-site inspection in January.
The visit to the site in Cheongju, the largest city in the nation’s North Chungcheong Province, was for an additional inspection in order to review new technology which was omitted in the facility’s most recent Current Good Manufacturing Practice (CGMP) report, with the FDA finding no issues requiring intervention.
Among the products manufactured at the facility is the drugmaker’s three-in-one oral treatment for HIV, known as CT-G07, which is currently awaiting approval from the FDA for commercialisation in the US. Celltrion is hoping for a decision as early as April this year.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

FDA grants De Novo authorisation to light-filtering device for migraine
The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …






